European Commission

Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

  • by

Shots: The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, NSCLC, glioblastoma, ovarian, cervical, and renal cancer as part of a specific regimen The approval follows CHMP’s positive opinion and is valid in all EU… Read More »Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

EU seeking ‘urgent clarification’ on Johnson & Johnson Covid vaccine delay

  • by

Company has said it is postponing deployment in Europe following concerns about blood clots in US Coronavirus – latest updates See all our coronavirus coverage The European commission is seeking “urgent clarification” from Johnson & Johnson after the company’s “completely unexpected” announcement that it has… Read More »EU seeking ‘urgent clarification’ on Johnson & Johnson Covid vaccine delay

EU Covid incompetence leaves governments wanting vaccines, not excuses | Larry Elliott

  • by

Centralised approach was meant to underline Europe’s solidarity but has had opposite effect The EU has made an almighty hash of procuring treatments for Covid-19. Vaccine centres are running short of supplies as a result. National governments want jabs rather than excuses for what has… Read More »EU Covid incompetence leaves governments wanting vaccines, not excuses | Larry Elliott

Biogen’s Plegridy (peginterferon beta-1a, IM) Receives EC’s Approval for Relapsing-Remitting MS

  • by

Shots: The approval is based on data assessing bioequivalence and AEs associated with IM administration vs SC administration of Plegridy in healthy volunteers Result: The data showed that participants receiving therapy through IM experienced fewer injection site reactions (14.4 vs 32.1 %), safety profiles were… Read More »Biogen’s Plegridy (peginterferon beta-1a, IM) Receives EC’s Approval for Relapsing-Remitting MS